Page 92 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $15.47
52wk Low $7.88 Greenwich LifeSciences, Inc GLSI $8.41
Building 14
Stafford, TX 77477

(USD - in millions) greenwichlifesciences.com
Market Cap 112.6
Enterprise 108.8
Basic Shares Out. 13.85 COMPANY OVERVIEW
Float 6.59
Institutional Holdings 10.09% Detailed Analysis:Channelchek.com
Short Interest 1.35
Avg. 90-Day Volume 0.07 Greenwich LifeSciences is a clinical-stage biopharmaceutical company
focused on the development of GP2, an immunotherapy to prevent
breast cancer recurrences in patients who have previously undergone
surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2
EPS Data protein, a cell surface receptor protein that is expressed in a variety of
common cancers, including expression in 75% of breast cancers at low
2022 2023 2024 (1+), intermediate (2+), and high (3+ or over-expressor) levels.
CQ1 (0.15) (0.17) (0.19) Greenwich LifeSciences has commenced a Phase III clinical trial,
CQ2 (0.06) (0.13) (0.20) FLAMINGO-01.

CQ3 (0.18) (0.19) (0.20)
CQ4 (0.22) (0.21) (0.61)
CY (0.61) (0.69) (1.21) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.16
ROE (ttm) -543.43
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
Building 14 Stafford TX 77477

Key Executives
CEO: Patel, Snehal
CFO: Patel, Snehal
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures